Objective:To investigate the effect of Shen Fu injection combined with chemotherapy on hematopoietic and immune function in patients with middle and advanced non-small cell lung cancer (NSCLC).Methods:Totally 92 patients with middle and advanced NSCLC were randomly divided into the control group and the observation group,46 cases in each.The control group was treated with cisplatin combined with paclitaxel (TP)chemotherapy,and the observation group was with the combination of intrave-nous infusion of 60 mL/d.Both of the 2 groups were carried out for 4 cycles of chemotherapy.The changes of hematopoietic func-tion,humoral immunity and cellular immune function in 2 groups were detected and compared after chemotherapy.Results:Com-pared with those before chemotherapy,levels of peripheral white blood cell (WBC),hemoglobin (Hb)and platelet (PLT)of both groups increased firstly and then decreased after 1 week of chemotherapy till the end.And for the observation group,the level of WBC in peripheral blood was significantly higher than that of the control group (P <0.05 or P <0.01),and Hb and PLT level compared with the level of control group had no significant difference,but there was still significant difference with those before chemotherapy (P <0.05);in control group,the levels of serum IgG,IgA and IgM after chemotherapy and CD3 +,CD4 +T cell ratio and CD4 +/CD8 + all decreased,and the percentage of T cells in CD8 + increased (P <0.05 or P <0.01);while in the ob-servation group,levels of serum IgG,IgA and IgM,CD3 +,CD4 +T cell ratio and CD4 +/CD8 + ratio increased significantly,and the proportion of CD8 + T cells decreased significantly (P <0.05 or P <0.01);in addition,the observation group had less rate of leukopenia,nausea and vomiting and other adverse reaction than the control group (P <0.01).Conclusion:Shen Fu injection can effectively reduce the bone marrow suppression and immune suppression in NSCLC patients with chemotherapy drugs,restore the body′s hematopoietic function,and effectively improve the body′s humoral and cellular immune function.%目的：探讨参附注射液联合化疗对中晚期非小细胞肺癌（NSCLC）患者造血功能及免疫功能的影响。方法：选取中晚期 NSCLC 患者92例，随机分为对照组与观察组，每组46例。对照组采用顺铂联合紫杉醇（TP）方案进行化疗，观察组在对照组的基础上联合静脉滴注参附注射液60 mL／d，2组均进行4个周期的化疗。化疗后检测并比较2组造血功能、体液免疫及细胞免疫功能指标的变化情况。结果：与化疗前比较，化疗结束时至化疗后1周，2组患者外周血白细胞（WBC）、血红蛋白（Hb）及血小板（PLT）水平先降低后升高，且观察组外周血 WBC 水平显著高于对照组（P ＜0．05或 P ＜0．01），而 Hb 及 PLT 水平与对照组无统计学意义，但仍与化疗前差异显著（P ＜0．05）；化疗后对照组血清 IgG、IgA 及 IgM水平，CD3＋、CD4＋T 细胞比例及 CD4＋／CD8＋均降低，CD8＋T 细胞比例升高（P ＜0．05或 P ＜0．01）；而观察组血清 IgG、IgA 及 IgM水平，CD3＋、CD4＋T 细胞比例及 CD4＋／CD8＋比值显著升高，CD8＋T 细胞比例显著降低（P ＜0．05或 P ＜0．01）；此外，观察组白细胞减少、恶心呕吐等不良反应发生率显著低于对照组（P ＜0．01）。结论：参附注射液可有效减轻化疗药物对 NSCLC 患者的骨髓抑制及免疫抑制作用，恢复机体造血功能，并有效改善机体体液免疫及细胞免疫功能。
展开▼
